The latest five major advances in stem cell therapy!
Dynamic disinfection is a process of disinfection and cleaning of air and surfaces in indoor Spaces. A
zone.
Air purifiers, also known as "air cleaners", air purifiers, and purifiers, refer to decoration pollution that can absorb, decompose or convert various air pollutants (generally including PM2.5, dust, pollen, odor, formaldehyde, etc. , bacteria, allergens, etc.), household appliances that effectively improve air cleanliness, are mainly divided into household, commercial, industrial, and building. Air Sterilizer,Air Disinfector Purifier,Air Cleaner Machine,Air Disinfectant Spray Jilin Sinoscience Technology Co. LTD , https://www.contoryinstruments.com
1. AIVITA stem cell therapy in the United States to start brain tumor phase 2 clinical trial
AIVITA Biomedical, a biotechnology company focused on innovative stem cell applications, recently announced the first clinical trial of a phase 2 cancer trial for newly diagnosed glioblastoma (GBM) patients. The Integrated Brain Tumor Program at the University of California, Irvine (UCI) and the UCLA-UCI Alpha Stem Cell Clinic (ASCC) have received IRB approval to begin recruiting patients to receive AIVITA's ROOTOFCANCER therapy. The patient will receive autologous dendritic cells bearing tumor antigens as an adjuvant treatment after primary surgery plus chemotherapy. AIVITA's ROOTOFCANCER technology is currently also being used in a phase 2 clinical trial of ovarian cancer in the United States and in the commercial development of melanoma in Japan.
2.BioLineRx announces positive results in stem cell mobilization phase 3 clinical trials
BioLineRx announced a positive result for lead-inperiod in the GENESIS trial, a double-blind, placebo-controlled phase 3 trial comparing BL-8040 with granulocyte colony-stimulating factor (G-CSF) and G-CSF alone. Mobilization of hematopoietic stem cells (HSCs) for autologous transplantation in patients with multiple myeloma. The trial enrolled 30 patients and was reviewed by the Data Monitoring Committee (DMC) after approximately 10, 20, and 30 patients were completed to assess the safety and efficacy of treatment with BL-8040 plus G-CSF. BL-8040 is a short synthetic peptide used for stem cell mobilization and treatment of hematological malignancies and solid tumors.
The data showed that only one dose of BL-8040, 9/11 patients (82%) achieved a primary endpoint threshold of greater than or equal to 6x106 CD34 cells/kg after 2 blood component separations. In addition, 7/11 patients (64%) achieved a primary endpoint threshold greater than or equal to 6x106 CD34 cells/kg after one blood component separation. The results to date show that the use of a single dose of BL-8040 in combination with G-CSF to mobilize HSC is not only safe and tolerable, but also efficiently collects the number of cells and is expected to reduce blood component separation to one. Based on positive data from the top 11 patients, DMC recommended discontinuing lead-inperiod and immediately transferred to the randomized placebo-controlled portion of the study.
3. Activation of dormant retinal stem cells is successful and is expected to treat blindness
A group of researchers from the Icahn School of Medicine at Mount Icahn (Icahn School of Medicine at Mount Sinai) used a retinal cell called Müller glial cells (MG) to help blind mice recover some of their visual function after reprogramming MG through two gene transfer steps. . The study was recently published in Nature. In zebrafish, MG, a source of stem cells, is part of the retinal self-repair system: they can self-proliferate to replenish damaged retinal neurons. However, in mammals, MG lacks the ability to self-regenerate. Scientists can activate mammalian MG division, but it can damage normal tissues.
Dr. BoChen, associate professor of ophthalmology at the Icahn School of Medicine, Mount Sinai, is the lead researcher for the study. Next, Dr. Chen's team plans to conduct behavioral studies to determine if the mouse has resumed its ability to perform visual tasks and will be tested on human retinal culture tissue. These findings are expected to be developed as regenerative therapies for the treatment of diseases such as age-related macular degeneration and retinitis pigmentosa, as well as other eye diseases such as glaucoma.
4.Cellect and Cell2in work together to improve stem cell selection and amplification
CellectBiotechnology, a new stem cell production technology company, and Cell2in, a Korean company focused on improving cell quality, recently announced the signing of a cooperation agreement. According to the agreement, Cellect's technology platform ApoGraft? Will be with Cell2in's proprietary recognition technology FreSHtracer? In combination, the latter uses fluorescent dyes to characterize oxidative stress and thereby monitor stem cell quality. “Through this collaboration, we have the opportunity to further improve the overall selection and expansion of stem cells to achieve higher quality cells at lower cost than current industry standards,†said Dr. Shai Yarkoni, CEO of Cellect.
5. GIPartners acquires two companies to strengthen leadership in stem cell storage and reproductive services
GIPartners announced that it has completed the acquisition of two companies: Cryobank (CCB), the world's largest sperm and egg donor bank, and CordBloodRegistry (CBR), the world's largest stem cell collection and storage company. The combined company will operate under the name of CaliforniaCryobankLifeSciences, becoming a leader in the stem cell storage and reproductive services market. Through the acquisition of these two outstanding companies, the new company will provide complete family-centered services for nearly 700,000 families in more than 30 countries, including the collection and storage of cord blood and umbilical cord tissue, donor sperm and egg freezing , as well as fertility preservation services. GIPartners is a private investment company based in San Francisco.
Beijing Baiou Bowei Biotechnology Co., Ltd. has set up a cell line, which is a center for cell lines. It is specialized in providing cell lines with low generation, short cycle and good activity. With a number of domestic and foreign research and development units, biomedicine, third-party testing institutions, research institutes have a good and stable long-term cooperative relationship! Welcome customers to inquire!
Http://
new method of safe disinfection that does not cause harm or interference to people and the environment on
site.The charged particles and active oxygen components produced by the low-temperature plasma in the
equipment play a major role in the process of killing bacteria and viruses, and have the effect of
broad-spectrum sterilization. It can not only inactivate aerosol plankton in the air and bacteria
and viruses on the surface of object but also effectively decompose formaldehyde and volatile organic
compounds, degrade all kinds of bad smell and purify it Air environment.A small amount of high purity
There are many different technologies and media in air purifiers that enable it to provide clean and safe air to the user. Commonly used air purification technologies include: adsorption technology, negative (positive) ion technology, catalytic technology, photocatalyst technology, superstructured photomineralization technology, HEPA high-efficiency filtration technology, electrostatic dust collection technology, etc.; material technologies mainly include: photocatalyst, activated carbon, Carbon core filter technology, synthetic fibers, HEAP high-efficiency materials, negative ion generators, etc. Most of the existing air purifiers are composite types, that is, a variety of purification technologies and material media are used at the same time.